Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Other Non-Current Liabilities (2016 - 2025)

Marimed (MRMD) has disclosed Other Non-Current Liabilities for 15 consecutive years, with $100000.0 as the latest value for Q3 2025.

  • Quarterly Other Non-Current Liabilities changed 0.0% to $100000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Sep 2025, changed 0.0% year-over-year, with the annual reading at $100000.0 for FY2024, 0.0% changed from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $100000.0 at Marimed, roughly flat from $100000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $100200.0 in Q1 2021, with the low at $100000.0 in Q4 2021.
  • Average Other Non-Current Liabilities over 5 years is $100031.6, with a median of $100000.0 recorded in 2021.
  • Peak annual rise in Other Non-Current Liabilities hit 0.0% in 2021, while the deepest fall reached 0.2% in 2021.
  • Over 5 years, Other Non-Current Liabilities stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $100000.0, $100000.0, and $100000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.